Boundless Bio (NASDAQ:BOLD) reported a narrowed net loss for the full year 2025 and a strategic realignment of its oncology pipeline, prioritizing a novel kinesin degrader as it prepares to enter the next phase of clinical development.
The San Diego-based biotechnology firm, which specializes in extrachromosomal DNA (ecDNA) biology, posted a net loss of $58.2 million for the year ended Dec. 31, 2025, compared with a $65.4 million loss in the prior year.
The company’s cash position of $107.6 million is expected to fund operations into the second half of 2028, providing a sufficient window to achieve initial clinical proof-of-concept readouts for its lead programs.
The company’s updated strategy centers on BBI-940, an oral kinesin degrader.
Boundless confirmed that the U.S. Food and Drug Administration accepted the program’s Investigational New Drug (IND) application in January 2026.
Following this, the first-in-human KOMODO-1 trial is now open for enrollment, targeting patients with oncogene-amplified cancers.
In a simultaneous move to streamline resources, Boundless announced it will cease enrollment in the Phase 1/2 POTENTIATE trial.
This study was previously evaluating the combination of BBI-355 (a CHK1 inhibitor) and BBI-825 (an RNR inhibitor).
Management cited market considerations and the prioritization of the BBI-940 program as the primary drivers for the discontinuation.
Operating expenses reflected the company’s focus on R&D efficiency.
Research and development costs for 2025 were $44.8 million, down from $55.3 million in 2024, while general and administrative expenses remained relatively flat at $18.7 million.